肿瘤细胞治疗研究
英文原题：First CAR T-Cell Therapy Approved for Solid Tumors.
中国已批准首款靶向实体瘤的CAR T细胞疗法satricabtagene autoleucel（satri-cel），用于claudin 18.2阳性、HER2阴性的胃或胃食管结合部癌患者。
中国已批准首款靶向实体瘤的 CAR T 细胞疗法 satricabtagene autoleucel（satri-cel），用于 claudin 18.2 阳性、HER2 阴性的胃或胃食管结合部癌患者。该批准基于一项 II 期试验，该试验发现这些细胞延长了无进展生存期和总生存期。科学家对这一决定感到兴奋，但警告称仍需更多研究来提高 CAR T 细胞对实体瘤的疗效。
China has approved the first CAR T-cell therapy that targets solid tumors, satricabtagene autoleucel (satri-cel), for patients with claudin 18.2-positive, HER2-negative gastric or gastro-esophageal junction cancer. The approval stems from a phase II trial that found the cells increased progression-free survival and overall survival. Scientists are excited about the decision but caution that more research is necessary to improve the effectiveness of CAR T cells against solid tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。
